Biomedical Company Announces Clearance From FDA For Infertility Treatment

In a significant development that could transform the fertility treatment landscape, Femasys Inc. (NASDAQ:FEMY), a biomedical company, has announced that their product, FemaSeed, has received clearance from the Food and Drug Administration (FDA). This marks the first localized directional insemination product for women experiencing infertility, providing a fresh alternative to in vitro fertilization (IVF). $Femasys(FEMY.US)$